Enanta Pharmaceuticals Inc (ENTA) SEC Filing 8-K Material Event for the period ending Thursday, February 28, 2019

Enanta Pharmaceuticals Inc

CIK: 1177648 Ticker: ENTA

View differences made from one to another to evaluate Enanta Pharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Enanta Pharmaceuticals Inc.


Assess how Enanta Pharmaceuticals Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Enanta Pharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
Ticker: ENTA
CIK: 1177648
Form Type: 8-K Corporate News
Accession Number: 0001564590-19-006516
Submitted to the SEC: Wed Mar 06 2019 5:00:15 PM EST
Accepted by the SEC: Wed Mar 06 2019
Period: Thursday, February 28, 2019
Industry: Pharmaceutical Preparations
  1. Vote of Security Holders

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: